Efficacy of Pemetrexed Maintenance in East-Asian Patients Subgroup Analysis of a Phase III Study Comparing Pemetrexed versus Placebo in Non-Small Cell Lung Cancer (NSCLC) Following Platinum-Based Induction Chemotherapy

被引：0
|
作者：
Belani, Chandra P. [1 ]
Wu, Yi-Long [2 ]
Chen, Yuh-Min [3 ]
Kim, Joo-Hang [4 ]
Yang, Sung-Hyun [5 ]
Zhang, Li [6 ]
Peterson, Patrick [7 ]
Orlando, Mauro [8 ]
机构：
[1] Penn State Coll Med, Penn State Hershey Canc Inst, Hershey, PA USA
[2] Guangdong Gen Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[3] Natl Yang Ming Univ, Sch Med, Dept Chest, Taipei Vet Gen Hosp, Taipei, Taiwan
[4] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[5] Korea Canc Ctr Hosp, Dept Hematooncol, Seoul, South Korea
[6] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
[7] Eli Lilly & Co, Corp Ctr, Indianapolis, IN USA
[8] Eli Lilly Interamer Inc, Dept Med, Buenos Aires, DF, Argentina
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S373 / S373
页数：1
相关论文
共 50 条
  • [1] Phase II study of maintenance therapy with pazopanib or pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following platinum-based chemotherapy.
    Konduri, Kartik
    Smith, David
    Compton, Natalie
    Lockheed, Denise Elmore
    Chakrabarti, Debasis
    Bhatt, Kamal
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [2] PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Reck, Martin
    Paz-Ares, Luis G.
    de Marinis, Filippo
    Molinier, Olivier
    Sahoo, Tarini Prasad
    Laack, Eckart
    John, William
    Zimmermann, Annamaria H.
    Visseren-Grul, Carla
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (02) : 205 - 213
  • [3] TOLERANCE AND EFFICACY OF CHEMOTHERAPY WITH PLATINUM AND PEMETREXED IN ELDERLY PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Leprieur, Etienne Giroux
    Labrune, Sylvie
    Giraud, Violaine
    Gendry, Thierry
    Cobarzan, Daniel
    Chinet, Thierry
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1285 - S1286
  • [4] Efficacy of pemetrexed-cisplatin (PC) in East Asian patients (pts): Subgroup analysis of a phase III study comparing PC versus gemcitabine-cisplatin (GC) in first-line treatment of advanced non-small cell lung cancer (NSCLC)
    Orlando, M.
    Lee, J. S.
    Yang, C.
    Simms, L.
    Park, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (01) : 23 - 28
  • [6] A randomized multicenter phase II study of concurrent pemetrexed and radiotherapy with induction or adjuvant cisplatin/pemetrexed in patients with unresectable stage III non-small cell lung cancer (NSCLC)
    Germonpre, Paul R.
    Janssens, Annelies
    Galdermans, Danny
    Ortmanns, Paul
    Deschepper, Koen
    Devogelaere, Roger
    De Droogh, Els
    De Pooter, Christel
    Goor, Chris
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S853 - S853
  • [7] Impact of platinum/pemetrexed versus other platinum-based regimens on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
    Zhai, Xiaoyu
    Wang, Ziping
    Yang, Lu
    Zhu, Yixiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer
    Jung, Yun Duk
    Lee, Sang Bin
    Jung, Yun Wha
    Song, Jung Sub
    Woo, In Sook
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (05): : 923 - 925
  • [9] Pemetrexed-based chemotherapy in advanced nonsquamous non-small cell lung cancer (NSCLC).
    Alshehri, Abdulrahman Ali
    Alsubait, Saud Abdullrhman
    Alamgir, M. Ahsan
    Park, Chandler
    Wen, Sijin
    Luo, Jin
    Ma, Patrick
    Monga, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum non-pemetrexed doublet chemotherapy
    Marshall, R.
    Kakoudaki, M.
    Danson, S. J.
    Fisher, P. M.
    Hatton, M. Q.
    Lee, C. E.
    Das, T.
    Bates, E.
    Woll, P.
    Taylor, F.
    LUNG CANCER, 2017, 103 : S31 - S31
12345